Inovio Pharmaceuticals Inc (NASDAQ:INO) has been working on a vaccine candidate targeted at COVID-19. The business guru is pleased to pronounce its interim clinical data. It has made a significant step forward, considering that its vaccine has found a slot in the non-human primate challenge study. The US government has been spearheading Operation WarpSpeed, which happens to be initiative linked to the provision of some safe products for consumption by the American population by 2021.

Trials

Inovio has been making some changes; lately, one of them being addition of some older participants in its expanded Phase 1 trial. If all moves according to plan, it hopes to kickstart its Phase 2/3 efficacy probably this summer. However, that will be dependent on the state of affairs in line with the regulatory concurrence.

The CEO of INOVIO, Dr. J. Joseph Kim, has given a few remarks in line with the progress made so far. Kimis quite impressed by all the participants that volunteered to participate in the company’s trial. He is also grateful to the investigator staff, which has been co-operative all along. The trial has been a successful one, according to him.

Inclusion of vaccine in Operation Warp Speed

Kim noted the inclusion of their product into the Operation Warp Speed. The official revealed that their product proved effective in the abrogation of the viral replication. This was a conclusion arrived at by considering the lungs of mice as a case study.

The leader says that the company remains dedicated to its promise advancing its INO-4800. This happens to be the only nucleic based vaccine that has shown stability at room temperature, considering a time-frame of about a year.He says that it is impressive that it is not necessary to freeze the product to transport it. Kim says that the nature of the vaccine makes it favorable when the world is battling COVID-19. It is a deadly diseases that continues claiming any lives globally. Experts and leaders globally agree that the mass immunizations are currently the way to go in staging a strong fight against the deadly disease.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.